PDC*line Pharma presents first clinical results from Phase I/II trial with PDC*lung01 at ESMO 2022
Preliminary results with PDC*lung01 in monotherapy and at low dose with pembrolizumab evoke acceptable safety profile, immunological activity and
Founded in April 2014 in Grenoble (France) as a spin-off of the French Blood Bank (Etablissement Français du Sang, EFS), PDC*line Pharma is a Belgian-French biotech company that is developing a novel class of off-the-shelf cancer immunotherapies based on a proprietary Plasmacytoid Dendritic Cell line (PDC*line) pre-loaded with peptides that are derived from target tumor antigens. Based on a robust preclinical package and a first-in-human phase Ib feasibility study in melanoma, PDC*line Pharma is focusing on lung cancer with a new candidate in clinical development (PDC*lung) and on neoantigens (PDC*Neo). PDC*line Pharma comprises a team of highly skilled professionals based in Liège (Belgium) and Grenoble (France).
Induction of a strong cytotoxic immune response directed against a selection of tumour antigens
Simple production of a large quantity of a highly qualified off-the-shelf product
The peptides can easily be changed to target a specific cancer type
PDC*line, our proprietary allogeneic cell line of Plasmacytoid Dendritic Cells solves the industrial limitations faced by immunotherapies based on dendritic cells currently on the market or in clinical development. Additionally PDC*line is much more potent than conventional dendritic cells to expand anti-tumor CD8+ T cells in vitro.
PDC*line Pharma represents a unique investment opportunity
Find out more information in our scientific publications
PDC*line Pharma solid Intellectual Property position rests on three pillars
PDC*line Pharma SAS
29 avenue du Maquis du Grésivaudan
38701 La Tronche
PDC*line Pharma SA
CHU - Tour 5 (B34) – GIGA
Avenue de l'Hôpital 11